Core Insights - Omada Health's 12-month analysis of its GLP-1 companion program shows significant weight loss among participants, with an average of 18.4% weight loss for those who persisted on medication, compared to 11.9% in real-world evidence [1][2] - The program demonstrated that members achieved 47% greater weight loss on semaglutide and 37% greater weight loss on tirzepatide compared to published real-world evidence [1][2] - Overall, participants in the program experienced an average weight loss of 16.3%, nearly double that observed in real-world analyses [1][2] Program Effectiveness - 67% of Omada members remained on their GLP-1 medications for one year, surpassing the 47-49% persistence rate found in comparable studies [2] - Members who discontinued medication before one year achieved a 13.1% average weight loss, compared to 6.8% among similar patients in other studies [2] Support and Care Model - Omada's Enhanced GLP-1 Care Track provides comprehensive support, helping members navigate their weight loss journey and manage medication side effects [3] - The program combines specialized GLP-1-focused care team support with tailored content, enhancing the medication experience for members [3] Real-World Data and Insights - Omada emphasizes the importance of real-world data, tracking outcomes in real-time to ensure the effectiveness of its programs as medications and access evolve [4] - The study is part of the Omada Insights Lab ANSWERS Initiative, which analyzes real-world data from behavior change weight health programs [4] Company Overview - Omada Health is a virtual healthcare provider focused on cardiometabolic conditions, including obesity, and supports members taking GLP-1s and other anti-obesity medications [5] - The company has served over one million members and has over 30 peer-reviewed publications demonstrating its clinical and economic results [6]

Core Insights - Omada Health's GLP-1 companion program significantly enhances medication persistence rates for GLP-1 medications, leading to improved weight loss outcomes comparable to clinical trials [1][2][4] Group 1: Medication Persistence and Weight Loss - Omada's analysis of 1,124 members showed that those who adhered to their GLP-1 medication for 24 weeks had a persistence rate of 84%, compared to lower rates in previous studies [2][4] - Members who maintained their medication lost an average of 12.1% of their body weight over 24 weeks, while those who discontinued early lost only 7.4%, indicating a 64% relative increase in weight loss for persistent users [2][4] Group 2: Support and Resources - The Enhanced GLP-1 Care Track provides targeted resources, including education on dose titration, side effects, nutrition guidance, and exercise support, to help members overcome barriers to medication persistence [3][4] - Omada aims to ensure that increased access to GLP-1 medications translates into sustainable long-term health benefits through enhanced support and engagement in healthy lifestyle changes [4][5] Group 3: Company Overview and Impact - Omada Health is a virtual-first healthcare provider focused on chronic disease management, with over a decade of experience and 29 peer-reviewed publications demonstrating its clinical and economic effectiveness [5][6] - The company serves more than 2,000 customers, including health plans and employers, and emphasizes a strong work culture, earning recognition as a Great Place to Work® [5][6]

Core Insights - Omada Health's GLP-1 companion program significantly enhances medication persistence, leading to weight loss outcomes comparable to clinical trials [1][4][6] - Real-world data indicates that many patients struggle with medication adherence, with one-third discontinuing GLP-1 use within the first month [2][3] - The Enhanced GLP-1 Care Track program provides targeted support to help patients overcome barriers to medication persistence, resulting in higher adherence rates [5][6] Group 1: Program Effectiveness - Omada's analysis showed that members who adhered to their GLP-1 medication for 24 weeks achieved an average weight loss of 12.1%, compared to 7.4% for those who discontinued early, representing a 64% relative increase [4] - The program demonstrated a persistence rate of 94% at 12 weeks and 84% at 24 weeks, significantly higher than previous studies which reported persistence rates ranging from 33% to 80% [3][4] Group 2: Support Mechanisms - The Enhanced GLP-1 Care Track offers comprehensive support, including education on dose titration, management of side effects, nutrition guidance, and exercise support [5][6] - Omada Health emphasizes the importance of providing resources to help members navigate healthcare options, particularly for those considering discontinuation due to access issues [5][6] Group 3: Industry Context - The increasing access to GLP-1 medications presents both opportunities and responsibilities for healthcare providers to ensure cost-effective and sustainable health benefits [6] - Omada Health has over a decade of experience and 29 peer-reviewed publications that validate its approach to chronic disease management and behavior change [7][8]